Sab Biotherapeutics Stock Analysis

SAB Stock Analysis Notes

About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.64. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. SAB Biotherapeutics recorded a loss per share of 3.68. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 5th of January 2024. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company was founded in 2014 and is based in Sioux Falls, South Dakota. Sab Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. To find out more about SAB Biotherapeutics contact the company at 605 679 6980 or learn more at https://www.sabbiotherapeutics.com.

SAB Biotherapeutics Investment Alerts

SAB Biotherapeutics Upcoming and Recent Events

SAB Largest EPS Surprises

View All Earnings Estimates

SAB Stock Institutional Investors

Note, although SAB Biotherapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

SAB Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.63 M.

SAB Profitablity

Management Efficiency

SAB Biotherapeutics has return on total asset (ROA) of (0.4186) % which means that it has lost $0.4186 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8192) %, meaning that it created substantial loss on money invested by shareholders. SAB Biotherapeutics' management efficiency ratios could be used to measure how well SAB Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.73 in 2025. Return On Capital Employed is likely to gain to -1.13 in 2025. At this time, SAB Biotherapeutics' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 24.9 M in 2025, whereas Other Current Assets are likely to drop slightly above 2.8 M in 2025.

Technical Drivers

As of the 10th of May, SAB Biotherapeutics owns the Information Ratio of (0.0002), market risk adjusted performance of (0.11), and Coefficient Of Variation of (5,291). In respect to fundamental indicators, the technical analysis model makes it possible for you to check possible technical drivers of SAB Biotherapeutics, as well as the relationship between them. Please validate SAB Biotherapeutics mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if SAB Biotherapeutics is priced fairly, providing market reflects its prevailing price of 1.79 per share. Please also confirm SAB Biotherapeutics jensen alpha, which is currently at 0.0027 to double-check the company can sustain itself in the future.

SAB Biotherapeutics Price Movement Analysis

SAB Biotherapeutics Insider Trading Activities

SAB Biotherapeutics Outstanding Bonds

SAB Biotherapeutics Predictive Daily Indicators

SAB Biotherapeutics Forecast Models

SAB Biotherapeutics' time-series forecasting models are one of many SAB Biotherapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary SAB Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how SAB Biotherapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling SAB shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as SAB Biotherapeutics. By using and applying SAB Stock analysis, traders can create a robust methodology for identifying SAB entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. SAB analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. SAB analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

SAB Biotherapeutics stock analysis indicators help investors evaluate how SAB Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading SAB Biotherapeutics shares will generate the highest return on investment. By understating and applying SAB Biotherapeutics stock analysis, traders can identify SAB Biotherapeutics position entry and exit signals to maximize returns.

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.